Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal.
biologic therapy
drug persistence
pharmacology
psoriasis
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
07
04
2022
received:
21
02
2022
accepted:
11
04
2022
pubmed:
15
4
2022
medline:
15
7
2022
entrez:
14
4
2022
Statut:
ppublish
Résumé
To characterize moderate to severe psoriasis (PsO) adult patients treated with secukinumab, estimate drug persistence and assess any reasons for treatment discontinuation. Non-interventional, retrospective, longitudinal record-based study including patients diagnosed with PsO who started secukinumab between January 2018 and January 2020. Baseline characteristics were analyzed by descriptive statistics; drug persistence and predictive factors were assessed through Kaplan-Meier curves and univariate and multivariate analysis, respectively. A total of 302 patients were included in the study: mean age was 48.4 years, 41.7% were female, median time since diagnosis was 12.9 years. 51.3% of patients were bio-naïve while 48.7% had previously been treated with biologics. PsO in difficult-to-treat locations (DTL) was present in 82.1% of patients, with scalp PsO in about half of patients. At 5-years follow-up, 84 patients discontinued secukinumab, 45 of which due to loss of efficacy. At week 104, overall treatment persistence was 71.7%. A higher probability of drug persistence was identified among those patients who initiated secukinumab ≥5 years after diagnosis, were bio-naïve or treated with only one previous biologic, had no PsO on DTL, and had diabetes mellitus. The predictive factors for discontinuation identified in our study were the start of secukinumab <5 years after diagnosis (p = 0.001), the bio-experimented status with ≥2 biologics (p = 0.007), and the presence of PsO on DTL (p = 0.014). A time since diagnosis of ≥5 years, naïve status or previous use of only one biologic are predictors for secukinumab persistence, whereas the presence of PsO on DTL predicts drug discontinuation.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biological Products
0
secukinumab
DLG4EML025
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15510Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity. JAMA Dermatol. 2013;149(10):1173-1179. doi:10.1001/jamadermatol.2013.5015
Torres T, Filipe P, Selores M. Impact of biosimilars in psoriasis treatment. Acta Med Port. 2013;26(6):646-648.
García-Sánchez L, Montiel-Jarquín ÁJ, Vázquez-Cruz E, May-Salazar A, Gutiérrez-Gabriel I, Loría-Castellanoso J. Quality of life in patients with psoriasis. Gac Med Mex. 2017;153(2):185-189.
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10. doi:10.1007/s00403-010-1080-1
European Medicines Agency. Summary of Product Characteristics Cosentyx. Accessed February 2, 2022. https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. doi:10.1056/NEJMoa1314258
Bagel J, Nia J, Hashim PW, et al. Secukinumab is superior to Ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb). 2018;8(4):571-579. doi:10.1007/s13555-018-0265-y
Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70-80.
Reich K, Arenberger P, Mrowietz U, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: week 80 results from the TRANSFIGURE study. J Am Acad Dermatol. 2017 Jun;76(6):AB232.
Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatology Venereol. 2018 Sep;32(9):1507-1514. doi:10.1111/jdv.14878
Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111. doi:10.1186/s13075-019-1882-2
Spindeldreher S, Karle A, Correia E, et al. T cell epitope mapping of secukinumab and ixekizumab in healthy donors. MAbs. 2020 Jan 1;12(1):1707418. doi:10.1080/19420862.2019.1707418
Daudén E, de Lima GPG, Armesto S, et al. Multicenter retrospective study of Secukinumab drug survival in psoriasis patients in a daily practice setting: a long-term experience in Spain. Dermatol Ther (Heidelb). 2021;11(6):2207-2215. doi:10.1007/s13555-021-00606-9
Torres T, Balato A, Conrad C, et al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81(1):273-275.
Bewley A, Hampton P, Riley E, et al. Secukinumab 300 Mg Demonstrates High and Sustained Effectiveness in Treating Patients with Moderate to Severe Plaque Psoriasis: Real-World Evidence from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). In: 6th Annual Practical Symposium, 8-11 August 2019, Beaver Creek; 2019.